Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - PubMed
6 days ago
- #venetoclax-obinutuzumab
- #BTK inhibitors
- #CLL/SLL
- Study compares real-world use of venetoclax-obinutuzumab (Ven-O) versus BTK inhibitors (BTKi) in first-line treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
- Among 148 patients, time-limited targeted therapy (Ven-O) was chosen for 51%, continuous BTKi for 44%, and chemotherapy-based regimens for 5%.
- BTKi was more frequently used in patients with del(17p)/TP53 mutation (84%), age >75 years (66%), and those living >100 km from an obinutuzumab-initiating center (70%).
- The study highlights personalized treatment selection influenced by age, genetic aberrations, geography, and patient preferences.
- Findings emphasize the need to reduce access barriers to time-limited therapies like Ven-O.